Novartis Breaks Ground in Denton: A Defining Moment for North Texas Innovation

This month, global healthcare leader Novartis officially broke ground on its new 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, marking a major milestone not only for the company, but for the continued evolution of the North Texas life sciences ecosystem. The site will become Novartis’ first manufacturing facility in Texas and its fifth RLT facility in the United States. 

The event brought together leaders from across the global healthcare and innovation landscape, including Novartis executives from Switzerland, state and local officials, healthcare providers, and regional ecosystem partners. BioNTX leadership, including CEO and CCO representation, joined fellow stakeholders and collaborators from organizations such as the Dallas Regional Chamber, BioLabs, and other regional innovation partners in recognizing what many view as a transformational investment for North Texas.

While the groundbreaking itself represented a major economic development win, the broader significance lies in what radioligand therapy represents for the future of cancer care. RLT is an emerging precision medicine approach designed to deliver targeted radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. Novartis has positioned itself as a global leader in this field, with expanding infrastructure intended to accelerate access to these therapies for patients nationwide. 

One of the most important voices at the event was Debra Patt, Executive Vice President of Policy and Strategy at Texas Oncology, whose presence underscored the increasingly critical role North Texas is playing in shaping the future of oncology innovation and patient care.

In reflecting on the significance of the project, Dr. Patt shared:

“The groundbreaking of the new Novartis RLT center in Denton Texas represents more than a building or a production line. It represents hope—hope rooted in innovation, science, and the conviction that we can do better for people living with cancer. We are excited at Texas Oncology to partner with Novartis in improving the lives of cancer patients through these novel therapies.”

Her remarks captured the deeper meaning behind the investment: the convergence of research, manufacturing, clinical care, and patient-centered innovation happening in real time across the region.

The project also highlights the strategic work being done to elevate Dallas-Fort Worth as a nationally competitive life sciences hub. Kelly Cloud and the team at the Dallas Regional Chamber have played an instrumental role in advancing the region’s life sciences recruitment efforts and positioning North Texas as a destination for global biotechnology investment. In a recent Dallas Regional Chamber article, Cloud noted that Novartis’ decision signals to the broader industry that Dallas-Fort Worth possesses the talent, infrastructure, and collaborative ecosystem necessary to support the next generation of advanced therapies.  

For BioNTX, the groundbreaking further reinforces the importance of sustained collaboration across industry, healthcare, academia, economic development, and innovation organizations. As North Texas continues to attract world-class investment and talent, BioNTX remains committed to helping convene and amplify the partnerships that move the ecosystem forward.

The Denton facility is expected to become operational in 2028 and create new jobs in bioengineering, advanced manufacturing, quality, and operations—adding another important layer to the region’s rapidly growing life sciences economy.